Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?
about
A comprehensive review of amyotrophic lateral sclerosisThe Granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticityStem cell transplantation for motor neuron disease: current approaches and future perspectivesTowards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans.ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the diseaseCharacterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease developmentGenetic and epigenetic regulation of the brain-derived neurotrophic factor in the central nervous system.Analysis of neurotrophic factors in limb and extraocular muscles of mouse model of amyotrophic lateral sclerosisALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unitGene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF.Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosisAnalytical sequence to study G-CSF effect on the transcriptome of isolated spinal motoneurons from SOD1 G93A mice, an animal model for amyotrophic lateral sclerosis.MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.Fabrication of growth factor- and extracellular matrix-loaded, gelatin-based scaffolds and their biocompatibility with Schwann cells and dorsal root ganglia.Expression of Wnt5a and its receptor Fzd2 is changed in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice.Intermittent hypoxia and stem cell implants preserve breathing capacity in a rodent model of amyotrophic lateral sclerosisUpdate of neurotrophic factors in neurobiology of addiction and future directions.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Extraocular Motor System Exhibits a Higher Expression of Neurotrophins When Compared with Other Brainstem Motor Systems.Stress-Induced CDK5 Activation Disrupts Axonal Transport via Lis1/Ndel1/Dynein.Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis.Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis.Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells.
P2860
Q26775401-84EC056E-26D6-41F3-B671-4CD781C38B71Q26798071-99343DA2-D594-4E85-B8B6-42DAA9FF674DQ26995278-2F5A4481-790D-4096-8987-0EC3A903AA37Q28067169-810AAEC4-F995-4F64-8ED3-61503387F71CQ28392297-A32CD576-FAC4-413A-8012-E87329E827B8Q28476121-FA9F09A2-FFCC-4F29-85AB-DFEBAB8E01CFQ33653087-21E347E3-D248-423F-8157-849A4A69A3E2Q34343728-143B9CE8-79FD-4214-9CA3-81BF06B7E1D7Q34554820-F858939F-A977-473B-97B2-268D2046E733Q34556952-D80D5B81-9B27-4176-B89D-8177071B37FDQ35555633-0250A22A-6930-4DAB-BFE3-B901905E3A4BQ35726226-904FCE02-E69E-49DF-9BA8-C0682C90EF64Q35814080-E426ED14-E9A0-4247-884B-A3F2798A9A09Q36157573-ED5A372F-B302-4ADA-8FA8-00DA378EF2F1Q36464568-79472B4D-412E-44A2-87A6-218A98D533B8Q36956184-F81B6ADF-9C02-4DA5-8D1D-7DB1B7F7C898Q37070017-61C5F8D8-03C5-4B3E-B3D2-0D4D29010AE6Q38770267-CF65C386-D9CF-4CB2-8294-2CC9D5A0C691Q38881707-7EC621C1-1F5B-4A5F-8A4C-ED1EE1BB44A7Q40974834-36680522-8C07-4F29-AC4D-031CF850B7FBQ41780599-C92F64AA-0F47-430D-9F69-80648BED32FAQ42285046-D7991B5F-6FC2-43BB-A93E-BA238A9E7F0CQ44704967-AFEFC385-80DF-42DE-A677-CA641F972716Q47152662-946C9775-07E4-4608-BF57-D60C7647949BQ47868914-55ED1BCF-1900-4543-988D-0E3D44B44E55
P2860
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@ast
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@en
type
label
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@ast
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@en
prefLabel
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@ast
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@en
P2860
P356
P1476
Neurotrophic growth factors fo ...... sclerosis: where do we stand?
@en
P2093
Alexandre Henriques
Claudia Pitzer
P2860
P356
10.3389/FNINS.2010.00032
P577
2010-06-11T00:00:00Z